Experimental data from FAP-Exd (AVA6103) demonstrates a more favorable profile compared to the marketed Antibody Drug Conjugate (ADC) Enhertu® LONDON and PHILADELPHIA, Feb. 24, 2026 (GLOBE NEWSWIRE) - ...
Because of advances in linker conjugation chemistry and our understanding of the ADC mechanism of action in vivo, an increasing breadth of anticancer agents are now being incorporated in newer ADC ...
(Alliance News) - Avacta Group PLC on Tuesday saw its shares rise, as it said new data demonstrates a favourable delivery profile and advantages of its preCision platform when compared to a marketed ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results